PharmNovo aims to provide safe and effective medicines for chronic pain therapy, based on novel Delta Opioid Receptor Agonists (DORAs). This is a very different target compared with conventional opioid drugs which are responsible for an epidemic of addiction and toxicity. We address the high unmet medical need for safe and effective treatments for chronic pain, which affects up to 30% of the adult population in the USA and Europe. Currently available treatments are not very effective and associated with severe side-effects. PharmNovo’s candidate compound, PN6047, is a completely new, biased signalling DORA that effectively reduces chronic pain in animal models and shows no tolerance or side-effects such as the respiratory depression and drug abuse associated with conventional opioids. PharmNovo AB is now seeking investors to fund large-scale production of the compound, GLP regulatory Toxicology, build up of the company and the preparation for Phase l clinical studies of PN6047 for chronic pain treatment.